



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY


ISAF Digital 2021



INTERNATIONAL
SEVERE ASTHMA
FORUM

isaf

International Severe Asthma Forum - 17 April 2021



FINAL PROGRAMME

[EAACI.org](https://www.eaaci.org)



Welcome to the ISAF Digital 2021 meeting!

We are offering you the opportunity to explore our rich state-of-the-art scientific content in a truly innovative way. By participating at the meeting you will be able to interact and discuss the latest findings in the exciting field of severe asthma.

Make the most out of your ISAF Digital 2021 experience by:

- **Accessing the meeting's virtual platform with your My EAACI login information;**
- Tuning in and watching a variety of virtual sessions without missing out;
- Discussing important topics and asking your questions via an interactive Q&A;
- Consulting our vast number of abstracts, posters and webcasted presentations with novel research any time during the meeting and afterwards;

In order to match this digital format, we have split the Meeting Programme in 3 parts:

Live Scientific Programme

Top-quality scientific sessions, to be delivered to you live during the event. You will find the details of this programme from pages 16 to 22.

Industry Programme

All the valuable content brought to you by our industry partners.

On-Demand Scientific Content

A selection of presentations from the live programme will be recorded and available for viewing during ISAF Digital 2021 and 6 months thereafter.



Welcome message	4	List of Posters	20
EAACI Committees	6	Sponsorship and Exhibition	24
General Information	7	Founder Sponsors	25
Description of Session Types	8	Company Sponsored Symposia	26
EAACI Future Events	11	Exhibitor and Sponsor List	27
EAACI Activity Challenge	12	Exhibitor and Sponsor Editorials	27
Networking Activities	13		
Programme at a Glance	16		
Programme - Saturday, 17 April	17		

General Contact

EAACI Headquarters

Hagenholzstrasse 111
3rd Floor
8050 Zurich Switzerland
Tel: +41 44 205 55 33
Email: events@eaaci.org

Press & Media Contact Information

EAACI Headquarters

communications@eaaci.org
Tel: +41 44 205 55 33
The EAACI Media and Embargo Policy is available [here](#).

Social Media Information

Follow EAACI for regular updates on our events, scientific content and more!

- [Facebook](#)
- [Twitter](#)
- [LinkedIn](#)
- [Youtube](#)

Welcome Message



Matteo Bonini
ISAF Digital 2021
Organizing Committee and
and EAACI Asthma Section
Chair



Stefano Del Giacco
ISAF Digital 2021 Co-Chair



Antonio Spanevello
ISAF Digital 2021 Co-Chair



Ibon Eguíluz-Gracia
ISAF Digital 2021 Co-Chair

Welcome to ISAF Digital 2021!

Welcome to the digital version of the International Severe Asthma Forum (ISAF Digital 2021). This focused meeting aims to bring together scientists and clinicians with a broad range of experience, from junior scientists/doctors to key opinion leaders, at an event dedicated to all aspects of severe asthma. The programme is designed to encourage scientific collaborations and facilitate the translation of emerging discoveries into clinical practice to benefit patients.

Through the online format, EAACI is delivering deliver state-of-the-art scientific content while following safety and health regulations. Delegates will still have the chance to interact and discuss the latest novelties in the area of severe asthma digitally, as we believe scientific exchange is a vital aspect of the ISAF experience.

We welcome speakers and participants from all over the world to share their knowledge and expertise with us and partake in a truly interactive interdisciplinary dialogue. We hope you enjoy our meeting!

M. Bonini *A. Spanevello*

Matteo Bonini

Antonio Spanevello

S. del Giacco *I. Eguíluz-Gracia*

Stefano Del Giacco

Ibon Eguíluz-Gracia

BECOME AN EAACI MEMBER

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Renew your membership today!

Benefits applied to all categories

- ✓ Free access to online Allergy, PAI and CTA journals
- ✓ Possibility to join Task Forces
- ✓ Full voting rights & eligibility for election
- ✓ 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- ✓ EAACI Annual Congress Up to 25% discount
- ✓ EAACI Focused Meetings 25% discount
- ✓ EAACI Schools & Master Classes Up to 40% discount

**For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€.*

Junior Membership (under 36 years old)

Free

- ✓ EAACI Annual Congress Up to 55% discount
- ✓ EAACI Focused Meetings Up to 70% discount
- ✓ EAACI Schools & Master Classes Up to 50% discount
- ✓ Eligibility for EAACI fellowships & Scholarships
- ✓ Eligibility for EAACI events travel grants

EAACI / NAS Dual Membership

30€

- ✓ EAACI Annual Congress Up to 25% discount
- ✓ EAACI Focused Meetings 25% discount
- ✓ EAACI Schools & Master Classes Up to 40% discount

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership

Discover our full membership offer at EAACI.org/membership or send an email to member@eaaci.org

ISAF Organising Committee

Matteo Bonini, EAACI Asthma Section Chair
 Ibon Eguíluz-Gracia, EAACI Asthma Section Secretary
 Stefano Del Giacco, EAACI Vice-President Education & Specialty
 Antonio Spanevello, EAACI Asthma Section Member
 Marek Jutel, EAACI President
 Ioana Agache, EAACI Past President
 Edward Knol, EAACI Vice-President Congresses

ISAF Scientific Programme Committee Maarten

Tomas Chivato, EAACI Vice-President Science
 Cezmi Akdis, EAACI Allergy Journal Editor in Chief
 Walter Canonica, EAACI Chair of the Methodology Committee
 Silvia Sanchez Garcia, EAACI Asthma Section Board Member
 Mariana Couto, EAACI Asthma Section Board Member
 Cristiano Caruso, EAACI Asthma Section Board Member
 Maarten Van de Berge, EAACI Asthma Section Board Member
 Ferda Oner Erkekol, EAACI Asthma Section Board Member

EAACI President

Marek Jutel, Poland

EAACI Vice-President Congresses

Edward Knol, The Netherlands

Login Information:

- In order for you to straightforwardly access our meeting's online platform we have developed a tool that allows you to use your My EAACI username and password as your ISAF Online Platform login.
- If you do not remember your My EAACI username and/or password, please access the platform [here](#) and go through the "Forgot your password?" process.
- Our support team is available to assist you in real time should any questions arise.

Abstracts

All abstracts will be listed on the EAACI website. Presented abstract texts will be published on the EAACI content platform after the event.

Certificate of Attendance

The Certificate of Attendance can be downloaded after completing the delegates survey, which will be sent via email after the event.

CME Credits

The International Severe Asthma Forum - ISAF Digital 2021, Online (originally Rome), Italy, 17/04/2021-17/04/2021 **has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 5 European CME credits (ECMEC®s)**. Please find more information here. Please find more information. Please find more information [here](#).

Disclaimer

Participants are encouraged to purchase an insurance to cover loss incurred in the event of cancellation. EAACI cannot be held liable for any hindrance or disruption of the ISAF Digital 2021 proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control (force majeure). Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only.

EAACI Campus

Visit the EAACI Campus virtual booth to learn more about EAACI's activities such as membership, publications, EAACI Media Library and future events is available under one roof. The booth will be open throughout the entire congress, and an online team will be available for questions through the live chat during the following hours:

- Saturday, 17 April 2021: 07:45 - 17:45 CET

Photography, film and audio for event documentation and public reporting

By participating in the ISAF Digital 2021 the delegate understands that recordings of the digital content and the capture of images and videos to be publicly shared are prohibited.

Registration

Registration fee for delegates includes full access to the event content.

Technical Information

The ISAF Digital 2021 interface will be user-friendly and fully responsive, allowing delegates to watch all sessions from their laptops/desktops, iPad/tablets, and mobile phones. However it is recommended to use computers, to get the best experience including live chat during sessions within the Live Scientific Programme, an important feature that boosts interaction between you, faculty and your peers. In regards to a preferable web browser, we suggest Google Chrome as the most compatible one. In order to provide a well streamlined support, we kindly ask you to send any technical queries directly to following email address: support@eaaci.org.

Timezone

The official ISAF Digital 2021 timezone is CET (Central European Time).

Virtual Exhibition

Join us in meeting with key industry experts, exchange knowledge on critical areas of development and research in allergy and immunology. The digital exhibition will be open according to the main scientific programme timetable, subject to final adjustments:

- Start of Exhibition: 17 April 2021 – 09:00 CET
- End of Exhibition: 17 October 2021 – 17:00 CET

Description of Session Types



Company Sponsored Symposia

Industry Symposia will run in parallel with the main scientific programme on the digital programme. These symposia are organised independently by the sponsoring companies who also select the topics and speakers. The topics have been reviewed and approved by EAACI.

Mentor Class

This session features a series of 5 min case report presentations, followed by a 10 min live discussion on each presentation, chaired by two senior experts. This is a unique opportunity to discuss case reports in a round table of peers and experts.

Sister Society Symposia

EAACI has collaborated with the Polish Society of Allergology to develop symposia that represent regional or scientific areas common to EAACI and the sister society. This is a chance to expand your knowledge beyond the traditional boundaries.

Symposia

Symposia are state-of-the-art educational sessions in which the speakers critically review diverse aspects of a specific topic. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area.

Poster Sessions

Posters can be found in the e-poster section of the ISAF Digital 2021, together with a voice-over, and available in the EAACI content platform. Poster chairs will interact with the poster presenters during the respective sessions. Three final winners will be selected from the list of each group's best posters. More information regarding poster prizes can be found [here](#).

Pro&Con Sessions

The Pro & Con Sessions allow speakers to debate controversial topics in an attractive format which provides "food for thought". The session may take the form of a debate where speakers alternate to present their arguments. Each presenter defends his/her position in a short presentation of maximum 10 minutes each, following by discussion with the audience for 5 minutes at the end of the session. The introduction and the conclusion of the Pro & Con session will be fully live, and the audience will be asked to vote at the beginning and the end of the session.



Impactful learning to further develop your knowledge in allergy, asthma and immunology





PAAM Digital 2021



7th Pediatric Allergy and Asthma Meeting - 12-13 November

Registrations opening soon!

Pick your next EAACI Event!



EAACI Hybrid Congress 2021

Harmonizing Research and Patient Care in Allergy, Asthma and Immunology

10-12 July 2021
Physical Congress in Krakow & Digital Congress

This year, we will focus on one of the overarching aims of our academy: ensuring standardization in our field across the globe, thereby facilitating knowledge mobility and providing the best degree of care to our patients worldwide.

Join us now for the biggest allergy meeting of 2021!

Focused meetings



PAAM Digital 2021
Pediatric Allergy and Asthma Meeting

PAAM Digital 2021 - Pediatric Allergy and Asthma Meeting
12-13 November

Join PAAM Digital 2021 together with thousands of pediatricians and primary care physicians who care passionately for the challenging scientific and clinical issues that relate to pediatric allergy and asthma.

For more information and registration to our events visit EAACI.org

EAACI.org

EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org

EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org

EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org

EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org

EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org EAACI.org



EAACI Activity Challenge



Overview

Delegates will be able to earn points at several check points and interactions along the way during the ISAF Digital 2021 experience. Your ultimate goal: **win vouchers that can be used towards any EAACI event registration or EAACI activity in the future.**

Available to all registered delegates during their visit to the virtual exhibition area when visiting, chatting, answering scientific questions, and providing valuable feedback to our industry partners.

Additionally, with the Leaderboard function, delegates will be able to see the live scores of the top 20 delegates.

EAACI would like to thank our Industry Sponsor for its support and dedication during these difficult times, This could not be done without their valuable contributions.

The digital information exchange at ISAF Digital 2021 represents a new and exciting experience for us all. We encourage you to explore it! Use your well-deserved breaks to network, get informed and exchange.

How does it work?

- Once you have logged on to the ISAF Digital 2021 platform, the Activity Challenge will appear on the Home Page. Click on the Activity Challenge icon which will prompt a description of the activities.
- The goal is to generate as many points as possible from the group of activities listed.
- Each activity will have a maximum amount of points that can be achieved, which will be distributed based on how much the attendee has completed.
- As activities progress, there are barriers that show:
 - Activity completion status. Eg. You have completed 5/10 activities
 - Participants' point total can be seen next to their profile.
- In the case of a tie between multiple participants in the EAACI Activity Challenge, the winners will be automatically identified based on the submission time of first completing the full Activity Challenge.



Activity Challenge ISAF Digital 2021


Networking Opportunities



Get in touch with your peers and expand your professional network!

Our events' networking tool has been developed to give you the element of interpersonal connection that we are missing from physical events. With just a few clicks you can explore the vast pool of delegates participating in the event, select your connections or view who is recommended to you based on your mutual interests, and start the discussion in a private one-on-one chat. One of EAACI's main goals is fostering such interaction among expert researchers and physicians, as only together the priorities of our specialty can be achieved. We encourage you to make use of the networking tool throughout the meeting.

Attendees List



Delegates can connect, chat and discover like-minded peers attending ISAF Digital 2021. It is possible to search for delegates through different criteria, such as profession, type of working place, location, and country. We recommend you check your pending requests as connection notifications come in. Make sure to update your profile, make it public and join the conversation!

Networking Lobby



This is where delegates meet "face-to-face". Turn on your webcam, activate your microphone and join the networking lobby for real-time interaction with other delegates. Grab your coffee and get ready to make new connections that will expand your professional network, discuss about science and the news, or simply catch up with that friend you haven't been to see in a long time.

Networking Breaks

Saturday, 17 April 2021

- 10:00–10:30 CET - **Networking Break**
- 11:30–11:45 CET - **Networking Break**
- 12:10–12:20 CET - **Networking Break**
- 12:45–13:30 CET - **Networking Break**
- 14:30–14:45 CET - **Networking Break**
- 15:45–16:15 CET - **Networking Break**
- As of 17:10 CET - **Main Networking Event**




Thousands of resources now available on EAACI Media Library

Guidelines
Abstracts
Books
Posters
Papers



**EAACI
WHITE
PAPER**


on Research,
novation,
Quality Care



**GLOBAL
ATLAS
OF
SKIN ALLERGY**

Published by the European Academy of Allergy and Clinical Immunology

www.eaaci.org




Newsletters



Webcasts

All EAACI Resources are only **1 click away**



Programme at a Glance

Saturday, 17 April 2021

This page gives an overview of the digital sessions organised on Saturday 17, 2021.

CET Time	Track 1	Track 2
08:45 09:00	Opening Remarks	
09:00 10:00	09:00 - 10:00 CET Session 1 The basics of severe asthma	09:00 - 10:15 CET Mentor Class on Severe Asthma Cases
10:00 10:30	Poster Viewing and Networking Break	
10:30 11:30	10:30 - 11:30 CET Session 2 Guidelines and Perspectives	
11:30 11:45	Poster Viewing and Networking Break	
11:45 12:10	11:45 - 12:10 CET Session 3 Pro&Con Session - Electronic Health in Severe Asthma	
12:10 12:20	Poster Viewing and Networking Break	
12:20 12:45	12:20 - 12:45 CET Session 4 Pro&Con Session - Immunotherapy in Severe Asthma (AIT)	12:00 - 13:15 CET Company Sponsored Symposia <i>Please note: this session will be offered in Spanish with English subtitles</i>
12:45 13:30	Lunch Poster sessions and Networking Break	
13:30 14:30	13:30 - 14:30 CET Session 5 Severe Asthma in special populations	13:30 - 14:45 CET Company Sponsored Symposia
14:30 14:45	Poster Viewing and Networking Break	
14:45 15:45	14:45 - 15:45 CET Session 6 Comorbidities in Severe Asthma	15:00 - 16:15 CET Joint Symposium EAACI & Polish Society of Allergology
15:45 16:15	Poster Viewing and Networking Break	
16:15 16:55	16:15 - 16:55 CET Session 7 - Keynote Lecture Severe Asthma and COVID-19	
16:55 17:10	Closing Remarks	
17:10	Networking Opportunity	



Programme description

Saturday, 17 April 2021

Session 1 - The Basics of Severe Asthma

09:00-10:00 CET

Chairs: Marek Jutel, Poland / Matteo Bonini, Italy

09:00 - 09:15 - **Mechanisms**
Cezmi Akdis, Switzerland

09:15 - 09:20 - **Q&A**

09:20 - 09:35 - **Phenotypes and Endotypes**
Kian Fan Chung, United Kingdom

09:35 - 09:40 - **Q&A**

09:40 - 09:55 - **Biomarkers**
Kenji Izuhara, Japan

09:55 - 10:00 - **Q&A**

Mentor Class on Severe Asthma Cases

09:00-10:15 CET

Chairs: Cristiano Caruso, Italy / Maarten Van de Berge, The Netherlands

09:00-09:05 - **CRO1: Late onset T2 asthma - a case study**
Catalina Cojanu, Romania

09:05 - 09:18 - **Q&A**

09:19 - 09:24 - **CRO2: Dupilumab therapy in a 17-year-old young woman with severe asthma**
Catharina Nitsche, Germany

09:24 - 09:37 - **Q&A**

09:38 - 09:43 - **CRO3: Allergic severe asthma and cat epithelia in covid-19 pandemic: a case report**
Paula Galván Blasco, Spain

09:43 - 09:56 - **Q&A**

09:57 - 10:02 - **CRO4: Benralizumab in severe eosinophilic asthma... Or is it something else?**
Joana Queirós Gomes, Portugal

10:02 - 10:15 - **Q&A**

Session 2 - Guidelines and Perspectives

10:30 - 11:30 CET

Chairs: Stefano del Giacco, Italy / Ibon Equiluz-Gracia, Spain

10:30 - 10:45 - **GINA Guidelines Update**
Antonio Spanevella, Italy

10:45 - 10:50 - **Q&A**

10:50 - 11:05 - **EAACI Biologicals Guidelines -Recommendations for Severe Asthma**
Ioana Agache, Romania

11:05 - 11:10 - **Q&A**

11:10 - 11:25 - **Imaging in severe asthma**
Parameswaran Nair, Canada

11:25 - 11:30 - **Q&A**

Session 3 - Pro&Con Session Electronic Health in Severe Asthma

11:45-12:10 CET

Chairs: Tomas Chivato, Spain / Cristiano Caruso, Italy

11:45 - 11:55 - **PRO**
David Drummond, France

11:55 - 12:05 - **CON**
Joao Fonseca, Portugal

12:05 - 12:10 - **Q&A**



Programme description

Saturday, 17 April 2021

Session 4 - Pro&Con Session Immunotherapy in Severe Asthma (AIT) 12:20 – 12:45 CET

Chairs: Ferda Oner Erkekol, Turkey / Antonio Spanevello, Italy

12:20–12:30 - **PRO**
Marek Jutel, Poland

12:30–12:40 - **CON**
Giorgio Walter Canonica, Italy

12:40 – 12:45 - **Q&A**

Session 5 - Severe Asthma in special populations 13:30–14:30 CET

Chairs: Mariana Couto, Portugal / Francesco Blasi, Italy

13:30–13:45 - **Severe asthma in women**
Apostolos Bossios, Sweden

13:45–13:50 - **Q&A**

13:50–14:05 - **Severe asthma in children**
Sejal Saglani, United Kingdom

14:05–14:10 - **Q&A**

14:10–14:25 - **Severe asthma in athletes**
Maia Rukhadze, Georgia

14:25 – 14:30 - **Q&A**

Session 6 - Comorbidities in Severe Asthma 14:45–15:45 CET

Chairs: Sebastian Johnston, United Kingdom / Apostolos Bossios, Sweden

14:45 – 15:00 - **Bronchiectasis**
Francesco Blasi, Italy

15:00 – 15:05 - **Q&A**

15:05 – 15:20 - **Chronic rhinosinusitis with nasal polyps**
Enrico Heffler, Italy

15:20 – 15:25 - **Q&A**

15:25 – 15:40 - **Alfa-1 antitripsin deficiency**
Marc Miravittles, Spain

15:40–15:45 - **Q&A**

Joint Symposium EAACI & Polish Society of Allergology 15:00 – 16:15 CET

Chairs: Piotr Kuna, Poland / Maciej Kupczyk, Poland

15:00–15:20 - **Focus on Patient. Personalised therapy for severe asthma**
Piotr Kuna, Poland

15:20 – 15:25 - **Q&A**

15:25–15:45 - **Diagnosis and allocation to biologics in severe asthma – guidelines of the Polish Society of Allergology**
Maciej Kupczyk, Poland

15:45 – 15:50 - **Q&A**

15:50–16:10 - **Biological severe asthma treatment in Poland - pros and cons of drug programme**
Aleksandra Kucharczyk, Poland

16:10 – 16:15 - **Q&A**

Session 7 - Severe Asthma and COVID-19 16:15 – 16:55 CET

Chairs: Giorgio Walter Canonica, Italy / Edward Knol, The Netherlands

16:15 - 16:50 - **Keynote Lecture:** Sebastian Johnston, United Kingdom

16:50 – 16:55 - **Q&A**



EAACI Hybrid Congress 2021

Madrid - Krakow, 10-12 July

Harmonizing Research and Patient care in Allergy Asthma and Clinical Immunology

This year's hybrid format will enable EAACI to build on the successful digital experience of EAACI Congress 2020: safeguarding your well-being and facilitating your participation wherever in the world you are based, while at the same time providing you access to valuable discussions within our community.

The physical part of the Congress will be organised in city of Krakow (Poland), selected for its suitability to our new format and physical accessibility. Previously planned to be held in Madrid, our Congress will retain its initial Spanish flavour thanks to the incredible work done on the scientific programme by our Scientific Committee.

The motto this year is "Harmonising Research and Patient care in Allergy, Asthma and Clinical Immunology", and as we well know, harmonisation of our practice is an effort that should be undertaken internationally.

We are looking forward to seeing you in Krakow and online!

EAACI.org



Saturday, 17 April 2021

12:45 - 13:30 CET

Group 1: Allergic Airway Disease

Chairs: *Cristiano Caruso, Italy / Dario Antolin Amerigo, Spain*

P24 – Prevalence and serodominance of dermatophagoides pteronyssinus mites in pediatric population with moderate-severe persistent asthma phenotype
Paloma Poza-Guedes, Spain

P63 - Changes In Heart Rate Variability Indicators In Children With Asthma, Depending On The Severity Of The Allergic History
Pavel Berezhanskiy, Russia

P62 - Efficacy And Safety Of Subcutaneous Immunotherapy For Allergic Rhinitis And Allergic Asthma In China
Juan Liu, China

P58 - Dyspnea In Young Man Suffering From Pollen Allergy – Not Always Asthma
Marika Gawinowska, Poland

P42 - Seafood Allergy Trends In The Asthmatic Population In The Dominican Republic: How Much Immune-Related Comorbidities Contribute To Increased Severity?
Leandro Tapia, Spain

P41 - Increased Environmental Allergy Severity Among Asthmatic Populations In Dominican Republic
Leandro Tapia, Spain

P40 - Association Of ABPA In Children With Poor Control Of Asthma
Manvi Singh, India

Group 2: Biomarkers

Chairs: *Maia Rukhadze, Georgia | Edward Knol, The Netherlands*

P82 - Systemic Production Of Nitric Oxide And IL-17A During Severe Allergic Asthma : Immunomodulation By The Helminth *Echinococcus Granulosus*
Sara Benazzouz, Algeria

P22 - Combination Of Transcriptomics And Genomics For The Identification Of Novel Loci Of Response To Asthma Treatment With Glucocorticosteroids

Natalia Hernandez-Pacheco, Spain

P16 - Differential Gene Expression Analysis Of Airway Remodeling Signaling Pathways In Severe Bronchial Asthma
Alena Minina, Belarus

P31 - Metabolomic Signatures Associated To Allergic Asthma Control With Differential Pharmacological Interventions. Applicability For New Biomarker Strategies
Maria Isabel Delgado-Dolset, Spain

P34 - Measurement Of EDN, MPO And NGAL In Nasal Mucosal Lining Fluid Vs. Blood
Eleftheria Pertsinidou, Sweden

P37 - Characteristics Of The Genomics And Metagenomics Of Asthma Severity (GEMAS) Study
Javier Perez-Garcia, Spain

P75 – Allergic and nonallergic asthma biomarkers prioritized by systems biology: sensitivity and specificity analysis
Lucia Cremades-Jimeno, Spain

P74 - CHI3L1 AND PI3: two time-stable asthma biomarkers able to discriminate asthma severity
Maria López-Ramos, Spain

P68 - Serum MicroRNAs As Tool To Predict Early Response To Benralizumab In Severe Eosinophilic Asthma
Jose Rodrigo-Muñoz, Spain

P66 - Serum MicroRNAs As A Tool To Catalogue Asthmatic Patients In Different Phenotypes/Endotypes Serving As Diagnostic And Prognostic Biomarkers Of The Disease
Marta Gil Martínez, Spain

P64 - Immunological Markers Of Glucocorticosteroids Insensitivity In Patients With Severe Asthma
Carlos Cardoso, Switzerland

P60 - Immunological Markers Of Secondary Immune Insufficiency In Patients With Severe Bronchial Asthma
Ella Churyukina, Russia

P54 - Transcriptome-Based Identification And Validation Of CRTH2 mRNA Levels In Peripheral Blood Of Adult Patients With Asthma
Asunción García-Sánchez, Spain

Saturday, 17 April 2021

P53 - Phenotypic Characteristics Of ILC2s And T- Lymphocytes In Donors And Patients With T2-Driven Bronchial Asthma
Alina Makeeva, Russia

P52 - Investigating The Effects Of Interleukin 33 On Rhinovirus A Induced Gene Expression Changes In Asthmatic Bronchial Epithelial Cells
Rebecca Cooper, UK

Group 3: Clinical management of asthma

Chairs: *Ferda Oner Erkekol, Turkey | Joao Fonseca, Portugal*

P83 - Severe Eosinophilic Asthma: Phenotypic Structure, Clinical And Functional Features
Darima Tsyndymeeva, Russia

P78 – Can near fatal asthma resolve severe uncontrolled T2-asthma?
Lucia Maria Porro, Italy

P76 - Altitude Climate Treatment (ACT) As An Alternative To Chronic Expensive Third Line Treatments In Severe Asthma: A Case Report
Marieke Drijver-Messelink, Switzerland

P72 - Roadmap To Improve Regional Care For Severe Asthma Patients In The Netherlands
Gert-Jan Braunstahl, The Netherlands

P12 – Phenotype of severe bronchial asthma with fixed air-flow obstruction
Angelina Kraposhina, Russia

P20 - Could Asthma Severity Level Impact The Perceived Importance Of Patient's Treatment Goals? Results From A Romanian Asthma Survey
Carmen Panaitescu, Romania

P21 - Multidimensional Severe Asthma Burden. Results From A Romanian Patient's Survey
Carmen Panaitescu, Romania

P32 - Correlations Between Airway Inflammation, Asthma Control And Pulmonary Function In Partly Controlled / Uncontrolled Asthmatic Indian Children
Rashmi Yadav, India

P61 - Loss Of Smell As A Reliable Clinical Biomarker For Severe Asthma And CRS With Nasal Polyps That Predict Sinus Occupancy
José Antonio Castillo, Spain

P57 - Challenges Of Silent Severe Asthma And NERD In Children
Gintare Liakaite, Lithuania

P56 - IgG4 Related Disease And Probable Severe Asthma
Dina Rnjak, Croatia

P50 - Difficulty In Diagnosing Paucigranulocytic Asthma In A Severe Steroid-Dependent Asthmatic
Ronina Covar, USA

Group 4: COVID-19 & psychological aspects of asthma

Chairs: *Cristina Boccabella, Italy / Ileana Ghiordanescu, Romania*

P86 - COVID-19 And Asthma In Children: Is There A Link ?
Valery Mukhortykh, Russia

P84 - Fatigue, General Psychological Distress And Specific Psychological Symptoms In A Severe Asthma Population Before And After Altitude Climate Treatment (ACT)
Karin Fietsen, Switzerland

P80 - Real-Life Impact Of COVID-19 Pandemic Lockdown On The Management Of Pediatric And Adult Asthma: A Survey By The EAACI Asthma Section
Ibon Eguiluz-Gracia, Spain

P77 - Effect Of The SARS-CoV-2 Pandemic On Treatment Processes Of Patients With Severe Asthma Who Were Receiving Monoclonal Antibody Treatment
Gokhan Aytekin, Turkey

P25 – The impact of COVID-19 in patients with severe asthma under biologic therapies
Ana Mesquita, Portugal

P36 - Presenting Prevalence, Characteristics And Outcome Of Asthmatic Patients With T2 Diseases In Hospitalized Subjects With COVID-19 In Madrid, Spain
Marcela Valverde-Monge, Spain

List of Posters



P30 - Health-Psychological Aspects In Persons With Severe Asthma

Lina Rönnebjerg, Sweden

P35 - Asthma Vs COPD And OSA In COVID19 Patients: Interesting Differences Among Groups

Marcela Valverde-Monge, Spain

P18 - Viral Respiratory Infection And The Link To Wheezing

Olena Mozyrska, Ukraine

P13 - Adherence to therapy and quality of life at severe bronchial asthma

Angelina Kraposhina, Russia

P29 - Relationship Of Health-Related Quality Of Life With Asthma Control And Airway Inflammation In Uncontrolled Asthmatic Indian Children

Rashmi Yadav, India

P43 - COVID-19 In Patients With Severe Asthma Treated With Biologics: Our Experience

Irina Bobolea, Spain

Group 5: Real life use of biologicals

Chairs: *Sejal Saglani, UK / Leyla Pur Ozyigit, UK*

P87 - Efficacy of Dupilumab in Patients With GINA-Defined Difficult-to-Treat Type 2 Asthma: LIBERTY ASTHMA QUEST Study

Jorge Maspero, Argentina

P85 - Biological Therapy Of Child Bronchial Asthma In Clinical Practice: What To Prefer And How To Choose?

Valery Mukhortykh, Russia

P81 - Lock In The Bud - The Resolving Effect Of Dupilumab In A Case Of Severe Refractory Asthma

Carmelo Sofia, Italy

P73 - One Patient, But Different Biologic Agents

Betul Dumanoglu, Turkey

P71 - Indirect Treatment Comparison Of Biologics In Severe Eosinophilic Asthma In Real Clinical Practice

Miramgul Dyneva, Russia

P70 - Profile of patients with biological therapies in the severe asthma unit of Merida Hospital, Spain

Alicia Mena, Spain

P11 - Real World Prompt Efficacy Of Mepolizumab In Severe Eosinophilic Asthma And Comorbid Chronic Rhinosinusitis With Nasal Polyps

Ruperto González Pérez, Spain

P17 - Mepolizumab as a steroid-sparing treatment option in a patient with eosinophilic granulomatosis with polyangiitis

Ana Presa, Portugal

P15 - Impact On The Quality Of Life Of Asthmatic Patients Treated With Benralizumab According To Mini-AQLQ Quality Of Life Test

Yaiza Bonilla Pacheco, Spain

P39 - Successful Therapy With Mepolizumab In Patient With Severe Eosinophilic Cough-Predominant Asthma

Joanna Hermanowicz-Salamon, Poland

P45 - Monitoring Disease Progression In Severe Non-Allergic Asthma Patients On Dupilumab Treatment - A Case Series

Inês Farinha, Portugal



ISAF Digital 2021

17 April

EAACI Founder Sponsors

EAACI and the Local Organising Committee gratefully acknowledge the support of our 2021 Founder Sponsors.

Platinum Founder Sponsors








Gold Founder Sponsors




Silver Founder Sponsors






Sponsorship and Exhibition

This section contains information that is promotional in nature, distinct from the scientific/educational elements of ISAF Digital 2021.

Company Sponsored Symposia



Saturday, 17 April 2021

COMPANY SPONSORED Session

Sponsored by Sanofi Genzyme / Regeneron

Please note: this session will be offered in Spanish with English subtitles



Impacto de la inflamación de Tipo 2 en la vía aérea. Una visión multidisciplinar / Impact of Type 2 inflammation on the airways. A multidisciplinary vision.

12:00 – 13:15 CET

- **Bienvenida / Welcome:** Antonio Valero
- **Visión del alergólogo de la vía aérea única: El asma y sus comorbilidades / Respiratory airway from Allergist's perspective: asthma and its comorbidities:** Jose Maria Vega Chicote
- **Visión del otorrino de la vía aérea única: La RSCcPN y sus comorbilidades / ENT's view of the respiratory airway: CRSRN and its comorbidities:** Alfonso del Cuvillo
- **Debate y preguntas / Questions and Discussion:** Antonio Valero, Jose Maria Vega Chicote, Alfonso del Cuvillo

COMPANY SPONSORED Session

Sponsored by Sanofi Genzyme / Regeneron



Dupilumab for the Treatment of Type 2 Airway Diseases: Expert Panel Discussion of Clinical Evidence and Experience.

13:30 – 14:45 CET

- **Opening Remarks & Panel Introductions:** G. Walter Canonica, Mona Al-Ahmad, Ludger Klimek
- **Type 2 Inflammation in Diseases of the Upper and Lower Airway:** Mona Al-Ahmad
- **Review of the Evidence for Dupilumab: Asthma:** G. Walter Canonica
- **Review of the Evidence for Dupilumab: CRSwNP:** Ludger Klimek
- **Panel Discussion and Audience Q&A:** G. Walter Canonica, Mona Al-Ahmad, Ludger Klimek
- **Clinical Experience With Dupilumab for the Treatment of Severe Type 2 Asthma and CRSwNP:** Mona Al-Ahmad, Ludger Klimek
- **Audience Q&A and Closing Remarks:** G. Walter Canonica, Mona Al-Ahmad, Ludger Klimek

Exhibitor & Sponsor List



Click on the icons to access content



Exhibitors and Sponsors	Virtual Exhibition	Digital Session
-------------------------	--------------------	-----------------

AstraZeneca



Sanofi Genzyme / Regeneron



SC Immunoeye SRL



Exhibitor & Sponsor Editorials

AstraZeneca PLC

1 Francis Crick Ave
CB2 0RE, Cambridge
United Kingdom
+44 20 3749 5000
www.astrazeneca.com

Respiratory & Immunology is one of AstraZeneca's three therapy areas and is a key growth driver for the Company.

AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019. Building on a 50-year heritage, the Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company's early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction.

Sanofi Genzyme / Regeneron

Binney Street 50
MA 02142, Cambridge
United States
+1 617 252 7500
www.sanofigenzyme.com

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients' needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.



Immunoeye SRL

520027, 27 Nicolae Bălcescu
Sfântu Gheorghe, Romania
+40 770 112 255
www.optimun.ro

Albert Optimun Medicals' mission is to take up-to-date medical services close to patients in a geographic area with a lack of certain fields and expertise. With 4 specialities (allergology, ophthalmology, cardiology, vascular surgery) we cater for more than 10 thousand patients annually. Besides developing our ophthalmological branch (with recently dded sterile ophthalmological operating-room), we equipped our allergology department with new instruments for precise diagnostics and follow-up to our asthmatic and allergic patients.



ISAF Digital 2021
17 April

EAACI Hybrid Congress 2021

Madrid - Krakow
10-12 July

Harmonizing Research and
Patient care in Allergy Asthma
and Clinical Immunology

EAACI.org

**EAACI 2021
HYBRID**



Madrid Digital

Krakow Hybrid



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY